Allarity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Landmark Phase 2 Results: Stenoparib Surpasses 25-Month Median Overall Survival in Advanced Ovarian Cancer Trial
Allarity Therapeutics Inc. has announced new and updated clinical data from its ongoing Phase 2 trial evaluating stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, in patients with advanced ovarian cancer. The results, which were presented at the American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer held September 19-21, 2025, in Denver, Colorado, show that median overall survival among platinum-resistant and refractory ovarian cancer patients receiving stenoparib/2X-121 twice daily has now surpassed 25 months. Clinical benefit was observed in patients with both BRCA wild-type and BRCA-mutated genetics. The company noted that two patients remain on therapy after more than 24 months, including one with primary platinum-refractory disease who remains alive more than two years after enrollment. The data are available via the scientific publications section of Allarity Therapeutics' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-090872), on September 24, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。